[CAS NO. 304456-62-0]  BTYNB

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [304456-62-0]

Catalog
HY-124447
Brand
MCE
CAS
304456-62-0

DESCRIPTION [304456-62-0]

Overview

MDLMFCD00977636
Molecular Weight309.18
Molecular FormulaC12H9BrN2OS
SMILESO=C(C1=CC=CC=C1/N=C/C2=CC=C(S2)Br)N

For research use only. We do not sell to patients.

Summary

BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA ( IC 50 =5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research [1] .


IC50 & Target

IC50: 5 μM (IMP1 c-Myc mRNA internation) [1]


In Vitro

The oncofetal mRNA-binding protein, IMP1 binds to and stabilizes c-Myc, β-TrCP1, and other oncogenic mRNAs, it leads to increased expression of the proteins encoded by its target mRNAs [1] .
BTYNB (10 uM; 0.5-1 hour) enhances the degradation rate of c-Myc mRNA in SK-MEL2 cells [1] .
BTYNB (10-40 uM; 72 hours) degrades c-Myc expression in a dose-dependent manner in SK-MEL2 cells [1] .
BTYNB (10-40 uM; 72 hours) decreases IMP1 expression in a dose-dependent manner in SK-MEL2 cells [1] .
BTYNB (1-40 μM; 72 hours) decreases levels of CDC34, CALM1, β-TRCP1, and Col5A1 mRNAs expression in T47D/(A1-2) cells in the presence of hormone [1] .
BTYNB elicits a robust dose-dependent inhibition of cell proliferation in IMP1-positive cells with IC 50 of 2.3 μM, 3.6 μM, and 4.5 μM in ES-2, IGROV-1, and SK-MEL2 cells, respectively. BTYNB has no effects on IMP1-negative cells and demonstrates no inhibition of cell proliferation at all concentrations tested, including 50 μM [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR [1]

Cell Line: T47D/(A1-2) cells
Concentration: 1 μM; 10 μM; 20 μM; 30 μM; 40 μM
Incubation Time:
Result: Reduced the levels of a diverse set of cancer-related IMP1 mRNA targets.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)


Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL ( 202.15 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2344 mL 16.1718 mL 32.3436 mL
5 mM 0.6469 mL 3.2344 mL 6.4687 mL
10 mM 0.3234 mL 1.6172 mL 3.2344 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

* All of the co-solvents are available by MCE.